Form D · Biotechnology
CAPRICOR THERAPEUTICS, INC.
Beverly Hills, CA · CIK 0001133869
Offering snapshot reported May 19, 2017 · SEC filing
- Reported sold
- $3.71M Offering amount: $3.71M
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 9, 2017 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| May 19, 2017 | Initial | $3,708,503 | No comparison | 4 | SEC filing |
| Mar 29, 2016 | Initial | $13,974 | No comparison | 24 | SEC filing |
| Feb 19, 2015 | Initial | $7,050,001 | No comparison | 8 | SEC filing |
| Feb 3, 2015 | Initial | $10,002,028 | No comparison | 39 | SEC filing |
| Feb 24, 2014 | Initial | $32,676 | No comparison | 1 | SEC filing |
| Dec 5, 2013 | Initial | $26,289,973 | No comparison | 34 | SEC filing |
| Jun 27, 2011 | Initial | $2,500,000 | No comparison | 6 | SEC filing |
| Jul 15, 2009 | Initial | $2,343,750 | No comparison | 24 | SEC filing |
| Sep 26, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-287105
Source: Form D, filed May 19, 2017. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Deborah Ascheim | Executive |
| Arie S. Belldegrun | Director |
| Anthony Bergmann | Executive |
| Richard B. Brewer | Director, Executive |
| Earl Collier | Director |
| Earl Collier, Jr. | Director |
| Anthony Davies | Executive |
| George Dunbar | Director |
| Daron Evans | Executive |
| Leland Gershell | Executive |
| Pedro Granadillo | Director |
| Louis Grasmick | Director |
| Andrew Hamer | Executive |
| Peter M. Kash | Director |
| Joshua Kazam | Director |
| Karen Krasney | Executive |
| Hsiao D. Lieu | Executive |
| Frank Litvack | Director |
| Louis Manzo | Director |
| Linda Marban | Director, Executive |
| Paul A. Mieyal | Director |
| Paul A. Mieyal, Ph.D. | Director |
| David Musket | Director |
| Gregory Schafer | Director |
| Rachel Smith | Executive |
| David M. Tanen | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
8840 Wilshire Blvd 2 Nd Floor
Beverly Hills, CA, 90211
Beverly Hills, CA, 90211